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Carcinoma of the esophagus 
Prognostic significance of histologic type 
Previous investigators have reported that in patients with esophageal carcinoma tumor cell type 
affects prognosis. A retrospective analysis of 258 patients, from 1985 to 1991, undergoing curative 
esophagogastrectomy for adenocarcinoma (n = 134) or squamous cell carcinoma (n = 124) was 
performed to test the hypothesis that histologic cell type is an independent prognostic factor and to 
identify other predictors of survival after resection. The actuarial overall survival (p = 0.16) and 
disease-specific survival (p = 0.68) were similar for adenocarcinoma (median overall survival = 27 
months) and squamous cell carcinoma (median overall survival = 22 months). Univariate analysis 
identified T stage, N stage, number of diseased nodes, tumor differentiation, tumor site, and blood 
transfusions as significant (p < 0.05) variables in predicting overall survival. The presence of 
Barrett's esophagus was not predictive of survival. Multivariate analysis demonstrated that T stage 
(p = 0.006), N stage (p = 0.01), and number of diseased lymph nodes (p = 0.03) were independent 
predictors of overall survival. This analysis demonstrated that histologic type is not an independent 
variable for overall survival in patients undergoing curative esophagogastrectomy for carcinoma of 
the esophagus and gastroesophageal junction. Outcome is most strongly influenced by extent of 
disease defined by T and N stage. (J TrlORAC CARDIOVASC SURG 1995;109:130-9) 
Michael D. Lieberman, MD (by invitation), Craig D. Shriver, MD (by invitation), 
Steven Bleckner, BS (by invitation), Michael Burt, MD, PhD, and the Thoracic and 
Gastric and Mixed Tumor Services, New York, N.Y. 
Over  the past decade an increase in the preva- 
lence of adenocarcinoma of the gastroesophageal 
junction and distal esophagus has been reported. I' z 
At Memorial Sloan-Kettering Cancer Center the 
proportion of gastric resections that encompassed 
the gastroesophageal junction has increased from 
31% in 1985 to 53% in 1992. Several investigators 
have suggested that histologic ell type affects prog- 
nosis in patients with esophageal carcinoma. 3-1° In 
previous studies, adenocarcinoma h s had a more 
adverse ffect on survival than squamous cell carci- 
noma, and poorly differentiated carcinoma has had 
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a more adverse effect than well or moderately 
differentiated carcinoma) -I° However, many of 
these studies were univariate analyses and included 
patients treated over a period of two decades. This 
retrospective analysis was performed to test the 
hypothesis that histologic type is an independent 
prognostic variable and to identify other predictors 
of survival after potentially curative esophagogas- 
trectomy in patients with esophageal carcinoma. 
Methods 
A computerized tumor registry of patients with the 
diagnosis of adenocarcinoma or squamous cell carcinoma 
of the gastroesophageal junction or esophagus treated at 
Memorial Sloan-Kettering Cancer Center from 1985 to 
1991 was reviewed to obtain the records of 258 patients 
undergoing curative resection. A retrospective chart re- 
view was performed to identify perioperative factors that 
may influence overall survival after tumor esection. Fol- 
low-up was completed through office charts and telephone 
interviews. Categorical nd continuous variables that were 
analyzed included age, sex, dysphagia, tobacco smoking, 
alcohol use, weight loss, operative procedure, splenec- 
tomy, blood transfusion, anastomotic leak, T stage, N 
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stage, number of diseased lymph nodes, tumor differenti- 
ation, Barrett's esophagus, margins, tumor site, and pre- 
operative chemotherapy or radiation therapy. 
Curative resection was defined as the surgical removal 
of all gross tumor in the absence of distant metastases and 
included the removal of locoregional lymph nodes. Gas- 
trointestinal continuity was reestablished byformation of 
a gastric tube and reanastomosis to the esophagus in the 
superior part of the mediastinum orneck. Tumor site was 
anatomically defined: proximal--cricopharyngeus to aor- 
tic arch; middle--extending from aortic arch to inferior 
pulmonary vein; distal--caudad to inferior pulmonary 
vein. Gastroesophageal junction tumors were included in 
this analysis f greater than 50% of the tumor mass was 
located in the esophagus. 
To assess the dependence of the rate of death caused by 
esophageal cancer on explanatory variables, we measured 
time from the date of operation to the date of death or last 
follow-up information. Survival was estimated for each 
variable by the product-limit method of Kaplan and 
Meier. 12 The log-rank test was used to check for depen- 
dence of survival on each categorical variable analyzed) 3 
A univariate proportional hazards regression was esti- 
mated and a likelihood ratio test was used to analyze the 
dependence of survival on each continuous variable. Pro- 
portional hazards regression was used to incorporate all of 
the explanatory variables in the same model, a4 Forward 
stepwise procedure and likelihood ratio tests were used to 
select he variables with e greatest prognostic value. The 
statistical nalysis was performed with the use of the SPSS 
statistical package (SPSS Inc., Chicago, Ill.). Frequency 
data were analyzed by the )(2 method. The critical signif- 
icance level of 5% was chosen. 
Results 
This study included 258 patients undergoing cur- 
ative resection of adenocarcinoma (n = 134) or 
squamous cell carcinoma (n = 124) of the esoph a- 
gus and gastroesophageal junction. The median age 
was similar for patients having adenocarcinoma (63 
years) and those having squamous cell carcinoma 
(64 years). The female/male sex ratio was 1:6.4 for 
adenocarcinoma and 1:1.6 for squamous cell tumors 
(p < 0.001). The most common presenting symptom 
was dysphagia (69%), particularly for patients with 
squamous cell carcinoma (squamous = 86% and 
adenocarcinoma = 52%, p < 0.001). Weight loss, 
defined as greater than 10% loss from premorbid 
body weight, was more common in patients with 
squamous cell tumors (56%) than in those with 
adenocarcinomas (27%), (p < 0.001). Most patients 
had a history of tobacco smoking (squamous = 82% 
and adenocarcinoma = 72%, p = 0.80) and alcohol 
use (squamous = 77% and adenocarcinoma = 56%, 
p = 0.08). Diagnosis was established by esophago- 
gastroscopy and biopsy. The tumor was located in 
the proximal esophagus in 6%, middle esophagus in 
Table I. Comparison of the prevalence of 
prognostic variables according to cell type 
Prevalence (%) 
Squamous ceil p Value 
Characteristic Adenocarcinoma carcinoma (X ~) 
Advanced T stage 78 65 0.03 
(T3) 
Node diseased 69 48 0.002 
>-4 Nodes diseased 50 35 0.08 
Poorly differentiated 46 33 0.06 
Blood transfusion 46 59 0.04 
21%, and distal esophagus or gastroesophageal 
junction in 73%. All adenocarcinomas (n = 134) 
were located in the distal esophagus or gastroesoph- 
ageal junction. 
Treatment was predominantly surgery alone (n = 
221), although a small number of patients received 
preoperative chemotherapy (n = 19), radiation ther- 
apy (n = 12), or chemoradiation ( = 6). All 
patients receiving preoperative chemotherapy or 
radiation therapy, or both, had squamous cell carci- 
noma. The primary operative procedures were 
transthoracic esophagogastrectomy (79%), transab- 
dominal esophagogastrectomy (9%), transhiatal 
esophagectomy (7%), and pharyngoesophagectomy 
(5%). Splenectomy was performed in 25% of pa- 
tients with adenocarcinoma (n = 33) and 10% of 
patients with squamous cell carcinomas (n = 12) 
(p < 0.01). Histologic tumor-flee margins were less 
than 2 cm in 42% of patients with adenocarcinoma 
and 17% of patients with squamous cell carcinoma 
(p < 0.0001). In-hospital mortality was 5% and was 
attributed to sepsis (pneumonia, n = 5; anastomotic 
leak, n = 4), hemorrhage (n = 2), cardiac embolism 
(n = 1), and pulmonary embolism (n = 1). The 
perioperative deaths occurred in three patients with 
adenocarcinoma and 10 patients with squamous cell 
carcinoma (p = 0.06). Twenty-six anastomotic de- 
hiscences occurred (10%) (adenocarcinoma, n = 14; 
squamous cell, n = 12; p = not significant). 
Table I provides a comparison of the prevalence 
of prognostic variables identified by univariate anal- 
ysis according to tumor type. Advanced T stage, 
presence of lymph node metastasis, four diseased 
lymph nodes or more, and poorly differentiated 
tumors were significantly more prevalent in patients 
with adenocarcinoma than in those with squamous 
cell carcinoma. However, patients undergoing resec- 
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Fig. 1. Overall survival according to the staging system of the American Joint Committee on Cancer 
Staging (1 versus 2A, p = 0.006; 1 versus 2B, p = 0.0006; 1 versus 3,p = 0.00007; 2A versus 2B, p = 0.004; 
2A versus 3, p = 0.016; and 2B versus 3, p = 0.89). 
Table II. Prognostic variables for overall survival 
after esophagogastrectomy for carcinoma of the 
esophagus or gastroesophageal junction 
Three-year 
survival 























64 T1 vs. T2,p = 0.18 
56 3"2 vs. T3, p = 0.03 
30 T1 vs. T3, p = 0.003 
56 NO vs. N1, p = 0.00004 
27 
56 0 vs. 1-3,p = 0.005 
37 1-3 vs. -->-4, p = 0.04 
18 0 vs. ---4, p < 0.00001 
41 0.05 
34 
45 Proximal vs. middle, p = 0.71 
29 Middle vs. distal, p = 0.02 
41 Proximal vs. distal, p = 0.55 
47 0.04 
31 
*Univariate analysis according t o log-rank test. 
ment for perioperative blood transfusion than did 
those with adenocarcinoma. 
Survival. The actuarial overall survival for all 
patients (n = 258) was 68%, 39%, and 27% at 1, 3, 
and 5 years, respectively. The overall median sur- 
vival was 26 months with a median follow-up of 18 
months. At the time of last follow-up 82 patients 
were alive with no evidence of disease, 36 patients 
were alive with disease, 127 patients had died of 
esophageal cancer, and 13 patients had died in the 
perioperative period. The 3-year overall survival 
according to the staging system of the American 
Joint Committee on Cancer Staging 11 included stage 
1, 80% (n = 19); stage 2A, 48% (n = 82); stage 2B, 
26% (n = 21); and stage 3, 29% (n = 136) (Fig. 1). 
Fig. 2, A and B demonstrates that tumor type was 
not a significant predictor of overall survival (p = 
0.16) or disease-specific survival (p = 0.68). The 
median overall survival was 27 months for patients 
with adenocarcinoma compared with 22 months for 
those with squamous cell carcinoma. The median 
disease-specific survival was 29 months for the ade- 
nocarcinoma group compared with 31 months for 
the squamous cell carcinoma group. Furthermore, 
overall and disease-specific survivals were not signif- 
icantly different according to cell type when adeno- 
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Fig. 2. A, Overall survival according to tumor type, p = 0.16. B, Disease-specific survival according to 
tumor type, p = 0.68. 
carcinoma was subdivided into adenocarcinoma 
arising in the presence (n = 36) or absence (n = 98) 
of Barrett's esophagus. The median overall survivals 
for patients with Barrett's adenocarcinoma, non- 
Barrett's adenocarcinoma, and squamous cell carci- 
noma were 28, 27, and 22 months, respectively (Fig. 
3). 
Table II illustrates the significant prognostic vari- 
ables identified by univariate analysis. T stage, N 
stage, number of diseased nodes, tumor differenti- 
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Fig. 3. Overall survival according to tumor type and Barrett's esophagus (Barrett's versus non-Barrett's 
adenocarcinoma, p = 0.80; Barrett's versus squamous cell, p = 0.41; and non-Barrett's adenocarcinoma 
versus squamous cell, p = 0.26). 
ation, tumor site, and blood transfusion were signif- 
icant variables in predicting overall survival. Of 
note, tumor type, age, sex, dysphagia, tobacco use, 
alcohol use, weight loss, Barrett's esophagus, oper- 
ative procedure, margins, splenectomy, and anasto- 
motic leak were not significant prognostic factors. 
Preoperative chemotherapy or radiation therapy did 
not improve survival in patients undergoing esopha- 
gogastrectomy for squamous cell carcinoma. Pa- 
tients with adenocarcinoma did not receive preop- 
erative adjuvant therapy. The median overall 
survivals for no preoperative therapy, preoperative 
chemotherapy, and preoperative radiation therapy 
were 34, 12, and 11 months, respectively. 
All demographic nformation, tumor characteris- 
tics, and treatment-related variables were then ex- 
amined in a Cox proportional hazards model (Table 
III). Multivariate analysis confirmed the importance 
of stage and number of diseased lymph nodes on 
overall survival. The 3-year overall survivals for T1 
(n = 22), T2 (n = 50), and T3 (n = 186) tumors 
were 64%, 56%, and 30%, respectively (p < 0.006) 
(Fig. 4). Patients without lymph node metastases 
(n = 103) survived longer than patients with lymph 
node metastasis (n = 155) (3-year survival; normal 
Table III. Multivariate analysis of overall survival 
after esophagogastrectomy f r carcinoma of the 
esophagus or gastroesophageal junction 
Variable p Value (Cox) 
T stage 0.006 
N stage 0.0l 
No. of diseased nodes 0.03 
Blood transfusion 0.07 
Spleneetomy 0.16 
Histologic cell type 0.17 
Tumor site 0.27 
Preop. chemotherapy 0.48 
Weight loss 0.52 
Tumor differentiation 0.66 
Age 0.70 
Anastom0tic leak 0.74 
Margin 0.78 
Preop. radiation therapy 0.81 
lymph nodes = 56%, diseased lymph nodes = 27%, 
p = 0.01) (Fig. 5). Furthermore, increasing number 
of diseased lymph nodes was an adverse prognostic 
variable as illustrated in Fig. 6. Three-year overall 
survivals for patients with normal nodes, one to 
three diseased nodes, and four or more diseased 
nodes were 56%, 37%, and 18%, respectively (p = 
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Fig. 4. Overall survival according to T stage, p = 0.006. 
0.03). The requirement for perioperative blood 
transfusion approached significance as an adverse 
factor. Three-year survival for blood transfusion 
(n = 134) was 31% and that for no transfusion 
(n = 124) was 47% (p = 0.07). 
Discussion 
This study demonstrated that outcome after cur- 
ative esophagogastrectomy is most strongly influ- 
enced by extent of disease defined by T stage, N 
stage, and number of diseased lymph nodes. Despite 
the greater prevalence of adverse prognostic fea- 
tures such as advanced T stage, metastasis to re- 
gional lymph nodes, tumor involvement in more 
than three lymph nodes, and poorly differentiated 
tumors, patients with adenocarcinoma and those 
with squamous cell carcinoma had similar overall 
and disease-specific survival. Histologic features in- 
cluding cell type, differentiation, and the presence of 
Barrett's esophagus were not independent prognos- 
tic variables. 
In contrast to this report, previous investigators 
reported a survival advantage for patients with 
squamous cell carcinoma compared with those hav- 
ing adenocarcinoma of the esophagus or gastro- 
esophageal junction. 3-I° Muller and associates, 3 in a 
review of 1201 papers on surgical treatment of 
esophageal cancer from 1980 to 1988, reported a 
lower 5-year survival for patients with adenocarci- 
noma than for those with squamous cell carcinoma, 
24% versus 18%. Mathisen and colleagues 4 re- 
ported a 5-year survival of 33.2% for patients with 
squamous cell carcinoma (n = 31) compared with 
7.7% for those with adenocarcinoma (n -- 73). A 
survival advantage for patients with squamous cell 
carcinoma may have been due to administration f 
preoperative chemotherapy to patients with squa- 
mous cell carcinoma. Lund and colleagues 5 docu- 
mented a disparity in 5-year survival between squa- 
mous cell (13%) and adenocarcinoma (2%) of the 
distal esophagus. Griffith and Davis, 6 in a study of 
distal esophageal carcinoma, demonstrated a sur- 
vival advantage for patients with squamous cell 
compared with adenocarcinoma. Furthermore, 
these investigators noted that squamous cell tumors 
of the middle esophagus had a worse prognosis than 
distal malignant tumors, 5-year survivals of 25% 
versus 16%. Matthews and Steel, 7in a small series of 
patients with resected carcinoma of the esophagus 
or gastroesophageal junction, reported a5-year sur- 
vival of 28% for squamous cell (n = 39) and 12% for 
adenocarcinoma (n = 33). The authors also noted 
that regardless of histologic ell type, patients with 
lymph node metastases had a poor survival. A large 
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Fig. 5. Overall survival according to N stage, p = 0.0l. 
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series from China compared overall survival for 
patients undergoing resection for tumors of the 
esophagus (n = 2032) and cardia (n = 1649). 8 The 
5-year survival was 47% for tumors of the esophagus 
and 24% for tumors involving the cardia. Unfortu- 
nately, information on histologic ell type was not 
available, but a reasonable assumption w uld be 
that most tumors of the esophagus were squamous 
cell and tumors of the cardia were adenocarcinoma. 
Only one study, a multicenter retrospective anal- 
ysis of 2400 patients with tumors of the esophagus 
and cardia, reported a survival advantage for pa- 
tients with adenocarcinoma compared with squa- 
mous cell carcinoma, 5-year overall survivals of 27% 
and 16%, respectively) 5 The studies demonstrating 
the prognostic significance of histologic cell type 
were univariate analyses ummarizing in some in- 
stances three decades of an institution's experience 
with carcinoma of the esophagus and including 
patients with noncurative r sections. Thus one must 
be cautious in interpreting the significance of histo- 
logic type on the basis of these data. 
Several studies indicated histologic ell type was 
not of prognostic significance. Skinner, Dowlat- 
shahi, and DeMeester, 16in an analysis of "favor- 
able" (T1, T2, or NO) carcinomas, reported that wall 
penetration and lymph node involvement were in-
dependent factors, but cell type and differentiation 
were not prognostic. This report, which is in concor- 
dance with our data, noted a more advanced stage at 
the time of diagnosis for patients with adenocarci- 
noma compared with squamous cell carcinoma. 
Another univariate analysis comparing adenocarci- 
noma of the gastroesophageal junction (n = 108) 
with squamous cell carcinoma (n = 104) of the 
esophagus had equivalent 5-year survivals, 18% 
versus 19%, respectively. 17 Three multivariate anal- 
yses controlling for stage failed to demonstrate 
prognostic significance of histologic ell type. Ellis, 
Gibb, and Watkins 18 confirmed the significance of 
stage, but cell type, age, sex, site, and duration of 
symptoms were not independent factors. A multiva- 
riate analysis of 100 patients with esophageal cancer 
demonstrated that stage and blood transfusion were 
independent prognostic factors, but cell type was not 
significant. 19 Lerut and associates, 2° in an analysis of 
257 patients with esophageal cancer, reported that 
TNM stage and lymph node status predicted sur- 
vival. No significant differences were observed ac- 
cording to tumor location, pathologic type, sex, or 
age. 2° Thus all studies in which multivariate analyses 
of prognostic factors were used emonstrated that 
histologic ell type, including Barrett's esophagus, i  
not an independent predictor of survival for patients 
with carcinoma of the esophagus or gastroesopha- 
geal junction. 
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Fig. 6. Overall survival according to number of diseased lympia nodes, p -- 0.03. 
Although histologic ell type was not a significant 
prognostic variable, poor prognostic factors were 
prevalent in patients with adenocarcinoma: d- 
vanced T stage, lymph node metastases, and more 
than three diseased lymph nodes. One possible 
explanation is that the lymph node dissection for 
gastroesophageal lesions, which are predominately 
adenocarcinomas, may have been more complete 
than for intrathoracic squamous cell lesions. Thus 
some of the NO squamous cell carcinomas may 
actually have been N1. Another explanation is that 
some patients (n = 33), 29%, with squamous cell 
carcinoma, in contrast o none of the patients with 
adenocarcinoma, received preoperative chemother- 
apy or radiation therapy, or both. This may result in 
preoperative downstaging of squamous cell carci- 
noma. Endoscopic ultrasonic (EUS) evaluation was 
performed in 10 of the 33 patients receiving neoad- 
juvant herapy. In our experience EUS has a greater 
than 90% concordance rate for T stage for tumors of 
the esophagus. 21 On initial EUS evaluation before 
neoadjuvant therapy, all 10 patients had EUS T3 
lesions. After neoadjuvant therapy and resection, six 
of 10 patients had pathologic T3 tumors. If one 
accepts that EUS is accurate for the assessment ofT 
stage for esophageal cancer, then in 40% of patients 
in whom EUS was performed the tumor was down- 
staged after preoperative chemotherapy or radiation 
therapy, or both. Thus downstaging as a result of 
neoadjuvant therapy may account for the disparity 
in pathologic stage between squamous cell carci- 
noma and adenocarcinoma. 
Although neoadjuvant therapy may have down- 
staged some squamous cell carcinomas, our results 
did not  show a survival advantage for patients 
treated with chemotherapy or radiation therapy, or 
both. Because preoperative chemotherapy may im- 
prove survival, 22 an additional analysis of patients 
receiving chemotherapy was performed. All patients 
receiving preoperative chemotherapy had T3 or N1 
disease clinically. Thus a comparison between pa- 
tients with squamous cell carcinoma receiving pre- 
operative chemotherapy (n = 25) versus no preop- 
erative chemotherapy and a T3 lesion (n = 65) or no 
preoperative chemotherapy and N1 disease (n = 50) 
would be appropriate to estimate the impact of 
preoperative chemotherapy. The median overall 
survival for patients with squamous cell carcinoma 
1 3 8 Lieberman et aL 
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having preoperative chemotherapy was 12 months; 
for those having no preoperative therapy and a T3 
lesion, 17 months; and for those having no preoper- 
ative therapy, 12 months. No significant difference in 
overall survival was noted among these treatment 
groups. 
Adenocarcinoma of the gastroesophageal junc- 
tion is becoming more prevalent in our center, as 
well as in other institutions. However, histologic ell 
type, including the presence of Barrett's esophagus, 
is not an independent prognostic factor. Patients 
with tumors of the esophagus or gastroesophageal 
junction typically have a poor outcome, but a highly 
selected group of patients undergoing curative re- 
section may enjoy long-term survival. In this series, 
3-year actuarial overall survival was 80% for stage 1, 
48% for stage 2A, 26% for stage 2B, and 29% for 
stage 3 disease. We have clearly demonstrated the 
importance o fT  and N staging in this disease. 
Furthermore, the number of diseased lymph nodes 
identifies subsets of patients with more aggressive 
disease and requirement for more aggressive ther- 
apy. The impact of preoperative chemotherapy is 
unclear, but novel therapeutic strategies and enroll- 
ment of patients in prospective trials must continue, 
particularly for patients with T3 or N1 disease. 
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Discussion 
Dr. Zwi Steiger (Detroit, Mich.). In search of common 
identifiable factors that may contribute to long-term sur- 
vival, we reviewed the charts of patients with squamous 
cell carcinoma of the esophagus between the years 1977 
and 1985. During this period 7.3% (37/507) patients 
survived 5years or longer. A total of 130 patients had no 
treatment because of advanced isease. Among those 
treated, 27.6% (104/377) had a combination of chemo- 
therapy, radiation therapy, and surgery; 6.1% (23/377) 
had surgery only; 18% (68/377) had radiation therapy 
only; and 48.3% (182/377) had chemotherapy and radia- 
tion therapy. Twenty-four percent (25/104) from the first 
group, 13% (3/23) from the second, 2.9% (2/68) from the 
third group, and 3.8% (7/182) from the fourth group were 
long-term survivors. I am aware that it is not possible to 
draw conclusions from this nonrandomized study except 
that in the first group a complete response to the combi- 
nation of chemotherapy and radiation therapy conferred a 
better chance for long-term survival. 
Dr. Jeffrey H. Peters. (Los Angeles, Calif.). I want to 
comment about he prognostic significance of the number 
of diseased nodes. As you know, the present staging 
system does not take into account the number of involved 
nodes, with NO disease being no involved nodes and N1 
disease being any involved nodes present. We have used 
an alternate staging system for this reason (WNM), 
believing that an intermediate group with between zero 
and four nodes i an important group of patients and can 
be differentiated prognostically. Your data also demon- 
strates this fact. Perhaps this present staging system 
should be modified. 
Dr. Robert J. Ginsberg (New York, N.Y.). In response to 
Dr. Peters, if one reads the instructions in the TNM 
staging system manuals, one will see that anyone can add 
an "A" and a "B" to any stage if there is a prognostic 
factor that is not listed there. Certainly our group, one of 
the leaders in esophageal surgery, should get in step with 
the rest of the world, try to conform to TNM staging, and 
abandon their own staging system. 
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